Covid, hyperimmune plasma used for the first time in the hospital in L'Aquila
Pregnant woman heals thanks to plasma from coronavirus patients.
Is the first time
Share
08 April 2021 The plasma of those recovered from Covid19 does not reduce the risk of respiratory worsening or death in the first thirty days.
This is what emerges from the data analysis of the randomized and controlled clinical trial called Tsunami, promoted by ISS and AIFA and coordinated by ISS, on the therapeutic role of convalescent plasma in patients who have developed the disease.
The analysis of the different subgroups confirmed the absence of significant differences between the two treatments, continue Aifa and Iss.
Only in the case of patients with less severe respiratory impairment (PaO2 / FiO2 ratio greater than or equal to 300 at enrollment) did a signal in favor of plasma emerge, which however did not reach statistical significance.
"This - indicate the authors - could suggest the opportunity to further study the potential therapeutic role of plasma in subjects with mild-moderate Covid and in the very early stages of the disease".
The treatment was overall well tolerated, although adverse events were more frequent in the group that received the plasma, the note continues.
The results of the Tsunami study are considered "in line with those of the international literature, mainly negative, except for cases of patients treated very early with high titre plasma".
According to the promoters, the Tsunami study, which involved a network of transfusion centers, virology laboratories and clinical centers on a national level, represents "a virtuous model of a research platform that confirms the ability of our country to produce high-level scientific evidence, even in emergency situations such as those that characterize a pandemic period. These evidences are indispensable for improving the quality of clinical care for the sick ".